Company Overview and News

to your dashboard

Headline News

Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year

2018-01-19 zacks
Shares of Agios Pharmaceuticals, Inc. (AGIO - Free Report) have soared 60.7% in a year’s time, outperforming the industry's increase of 25.1%. (98-0)

Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It?

2018-01-17 zacks
Shares of Novo Nordisk (NVO - Free Report) hit a new 52-week high of $55.72 on Jan 16, before eventually closing the day at $55.31. Shares of Novo Nordisk have gained 53.5% over a year while the industry registered an increase of 20.6%. (39-0)

Endo (ENDP) Loses 35% in a Year: Can It Turn Around in 2018?

2018-01-16 zacks
Shares of Endo International plc (ENDP - Free Report) have tumbled 35.4% over a year against the industry’s gain of 7.1%. (57-0)

What Do The Recent Gilead And Celgene Buyouts Foretell?

2018-01-16 seekingalpha
2017 top pick (Kite Pharma) paid off handsomely via the Gilead acquisition. M&As in the bioscience space are likely to continue into 2018. (119-0)

Aradigm's Bronchiectasis Candidate Has Negative FDA Vote

2018-01-12 zacks
Aradigm Corporation (ARDM - Free Report) announced that the FDA’s Antimicrobial Drugs Advisory Committee has voted against the approval (in the ratio of 12:3) of its lead candidate, Linhaliq (a mixture of liposome encapsulated and unencapsulated ciprofloxacin). Aradigm is looking to get Linhaliq approved for the treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients suffering chronic lung infections with pseudomonas aeruginosa. (90-0)

Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock?

2018-01-12 zacks
Shares of Perrigo Company plc (PRGO - Free Report) hit a new 52-week high of $92.16 on Jan 11, just a few days after the company announced the appointment of its new chief executive officer (CEO), Uwe Rohrhoff. The stock eventually closed at $91.99. (40-0)

Endo (ENDP) Gets Subpoena From Florida for Opioid Misuse

2018-01-12 zacks
Endo International plc (ENDP - Free Report) announced that its subsidiary, Endo Pharmaceuticals Inc. (EPI), received a grand jury subpoena from the United States Attorney's Office for the Southern District of Florida seeking documents and information relating to products containing opioid painkiller oxymorphone. (61-0)

Why is Novo Nordisk Stock Up More Than 50% in Past Year?

2018-01-11 zacks
Shares of Novo Nordisk (NVO - Free Report) have surged 55.4% in the past year, outperforming the 18% increase registered by the industry. Here we analyze the factors that led to the rally. (146-0)

Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up

2018-01-10 zacks
Shares of Adamas Pharmaceuticals, Inc. (ADMS - Free Report) increased more than 5% on Jan 9, after it announced a full commercial launch of its lead product, Gocovri, in the United States for treating dyskinesia in patients with Parkinson's disease (PD), who are on levodopa-based therapy. Significantly, this is the first and the only drug to receive an approval for this indication in the United States. (58-0)

Acorda's Shares Down on Disappointing Ampyra View for 2018

2018-01-09 zacks
Acorda Therapeutics, Inc. (ACOR - Free Report) announced preliminary sales numbers of its key multiple sclerosis drug, Ampyra, for the fourth quarter of 2017 and issued a financial outlook for 2018 at the JP Morgan healthcare conference. The company also provided a business update at the same. (51-1)

Novo Nordisk Confirms Bid for Ablynx But Faces Rejection

2018-01-09 zacks
Novo Nordisk (NVO - Free Report) confirmed that it has made a revised offer to buy Belgian biotech company — Ablynx NV  — on Dec 22, for 2.6 billion euros ($3.1 billion). This includes a total cash consideration of EUR 28.00 per share and one Contingent Value Right ('CVR') with total potential cash payments over time of up to EUR 2.50 per share. The proposal values the Belgian company about 14% more than Novo Nordisk’s first proposal, which was made on Dec 7. (39-0)

Synergy Pharmaceuticals' Trulance Enters Its Sophomore Year

2018-01-08 seekingalpha
Unfortunately, this was not enough to offset some very questionable decisions by management throughout the year in regards to the company’s finances. (274-3)

Are Options Traders Betting on a Big Move in Sucampo (SCMP) Stock?

2018-01-05 zacks
Investors in Sucampo Pharmaceuticals, Inc. (SCMP - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the January 19, 2018 $15 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. (42-0)

Celsion's Phase I/II Cancer Study Initiation Gets FDA Nod

2018-01-05 zacks
Celsion Corporation (CLSN - Free Report) announced that the FDA has accepted the design of its phase I/II study – Ovation II – in ovarian cancer and cleared it for initiation. The study will evaluate its DNA-based immunotherapy, GEN-1, as localized treatment for stage III/IV ovarian cancer in newly diagnosed patients. (58-1)

Emergent Starts Phase II Study on Anti-influenza Candidate

2018-01-05 zacks
Emergent BioSolutions Inc. (EBS - Free Report) announced that it has initiated a phase II dose-ranging study to evaluate its investigational immune globulin to treat influenza virus infection. (48-0)

CUSIP: 864909106